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cense.Abstract Introduction: RANTES (Regulated upon Activation, Normal T cells Expressed and
Secreted) is a potent chemoattractant peptide that has been shown to play a crucial role in inﬂam-
mation.
Aim of work: The aim of this study was to measure serum RANTES concentration and it clariﬁes
the effect of its functional promoter polymorphisms on the risk and activity of Rheumatoid arthritis
(RA).
Patients andmethods: Serum level of RANTES was measured using ELIZA in 47 patients with RA
and 15 healthy controls. They also were genotyped for RANTES-403G/A and -28C/G using PCR-
restriction fragment length polymorphism (PCR-RFLP).
Results: A signiﬁcant increase in serum RANTES level was observed between the RA groups, espe-
cially active patients, and controls with positive correlations with parameters of the disease activity.
As regards to RANTES (-403 G/A) polymorphism, individuals with A allele were at signiﬁcant
positive risk for RA but G allele were at negative risk for RA. It is noteworthy that this polymor-
phism was also associated with activity of the disease. On the other hand, there was no signiﬁcantm (H.M. Elsaadany).
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86 H.M. Elsaadany et al.difference in genotype and allele frequencies of the RANTES-28C/G polymorphisms when the
active RA, inactive RA, and control groups were compared.
Conclusion: High serum RANTES level in patients with RA especially active ones conﬁrmed its
role in RA pathogenesis. Its interesting association with parameters of disease activity may enable
rheumatologists to deﬁne RA patients who are at risk of developing activity within short periods of
time. G-403A polymorphism is associated with the development and activity of RA in Egyptians.
However, further larger scale population studies are necessary to clarify the role of this polymor-
phism in RA. If this will be proven, therapeutic antagonists to RANTES may lead to the develop-
ment of effective alternative treatment for RA, particularly in patients carrying the RANTES-403 A
allele.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Rheumatoid arthritis (RA) is characterized by inﬁltration of
mononuclear cells into synovium, enhanced angiogenesis and
the proliferation of the synovium-lining layer. Macrophages,
ﬁbroblasts, lymphocytes and endothelial cells in rheumatoid
synovium are supposed to contribute to the pathogenesis of
the disease by several mechanisms, including chemokines pro-
duction [1].
Chemokines is a superfamily of small (8–14-kd), structur-
ally related chemotactic cytokines, induced by inﬂammatory
cytokines, growth factors and pathogenic stimuli [2]. They
are primarily involved in the regulation of immune cells motil-
ity in their speciﬁc homing to lymphoid organs in normal
hematopoiesis and during inﬂammation. In rheumatoid arthri-
tis, chemokines selectively mediate the recruitment and migra-
tion of activated leukocytes into the synovium at sites of
inﬂammation which causes tissue damage and have a central
role in inﬂammation [3].
To date 53 human chemokines and 23 receptors have been
cloned and characterized [4]. These chemokines are classiﬁed
into four families, CC, C, CXC and CX3C with two major
subclasses, the CXC and CC chemokines [5]. CXC chemokines
such as interleukin-8 (IL-8) have been implicated in acute
inﬂammation, since they exert their function mainly on neutro-
phils, whereas the CC chemokines, including RANTES and
monocyte chemoattractant protein 1 (MCP-1), attract and
activate a variety of cells, including monocytes, macrophages,
lymphocytes, eosinophils, as well as basophils have been impli-
cated in chronic inﬂammatory disease [6].
RANTES is a potent chemotactic agent for T lymphocytes
and monocytes and is expressed after cellular activation in
ﬁbroblasts, T cells, monocytes, endothelial cells, and certain
epithelial cells [7].
The human RANTES gene is located on chromosome
17q11.2-q12 with seven identiﬁed single nucleotide polymor-
phisms (SNPs), four in the promoter, including -403G/A and
-28C/G, two in the ﬁrst intron, and one in the 30untranslated
region [8]. Clinical associations of RANTES A-403 with
inﬂammatory diseases such as atopic dermatitis [9]; asthma
[10], polymyalgia rheumatica [11], sarcoidosis [12], diabetic
nephropathy [13], as well as susceptibility to HIV infection
and disease progression have been reported [14].
On the other hand, 28C/G promoter polymorphism is sig-
niﬁcantly associated with late-onset asthma [15], diabetic
nephropathy in type 2 DM [13] and SARS susceptibility [16].The aim of this study was to measure serum RANTES con-
centrations in RA patients, determine its correlation with clin-
ical manifestations and disease activity. Genotyping of
RANTES-403 and -28 polymorphism and its possible associa-
tion with RA were also evaluated.2. Patients and methods
2.1. Patients and samples
Forty seven patients with RA diagnosed according to the
American College of Rheumatology (ACR) classiﬁcation re-
vised criteria [17] were enrolled from outpatient clinic of the
Physical Medicine, Rheumatology and Rehabilitation and
Internal Medicine departments, Tanta University Hospitals.
They were divided into 2 groups, Group I, included 29 patients
(25 females and 4 males) with active RA aging from 20 to
51 years with a mean age of 38.1 ± 5.1 and group II, which in-
cluded 18 patients with inactive RA (16 females and 2 males)
aging from 23 to 52 years with a mean age of 39.2 ± 3.4. In
addition to 15 healthy individuals (12 females and 3 males)
served as control matched for both age and sex (group III).
Patients with atopy, DM type 2, cardiovascular diseases, renal
diseases and other autoimmune diseases were excluded.
All the patients were subjected to full history taking,
through clinical and musculoskeletal examinations with partic-
ular attention to the disease duration, number of the tender
joints and/or number of swollen joints. Disease activity was as-
sessed clinically using the modiﬁed disease activity score (DAS
28) [18]. Laboratory assessment was done using Erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), rheuma-
toid factor (RF), and total leukocytic counts (TLC).
2.2. Measurement of serum level of RANTES using ELISA
Serum level of RANTES was determined by commercial
enzyme-linked immunosorbent assay (ELISA) kit for RAN-
TES (Bender MedSystems, Inc., USA) according to the manu-
factures instructions.
2.2.1. Identiﬁcation of RANTES genotypes
Genomic DNA was extracted from EDTA peripheral blood
using QIA amp blood kit (Qiagen, Germany) following the
manufacture instructions. Extracted DNA concentration was
determined by spectrophotometry at 280 nm.
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of RANTES gene were determined by PCR-RFLP method.
The sequences of forward and reverse primers for both poly-
morphisms were
 50-GCC TCA ATT TAC AGT GTG-30 and
 50-TGC TTA TTC ATT ACA GAT GTT-3 [19].
 50-ACA GAG ACT CGA ATT TCC GGA-30 and
 50-CCA CGT GCT GTG TTG ATC CTC-30 [15,20]
respectively.
Each reaction mixture (20 ll) contained approximately
200 ng of DNA template, 1 U of Taq DNA polymerase,
25 pmol of each primer, 200 lM dNTP, 20 mM Tris–HCl
(pH 8.4), 50 mM KCl, and 1.5 mM MgCl2. PCR cycles were
as follows: 95 C for 2 min followed by 35 cycles each of
95 C for 40 s, 50 C for 40 s, and 72 C for 40 s. A ﬁnal exten-
sion step was carried out at 72 C for 5 min [19].
A resultant DNA products of 135 bp for -403G/A and
173 bp for -28C/G genotypes were obtained. In 1· restriction
buffer a 10 ll of these DNA products were digested either
overnight at 55 C, using MaeIII (Roch Diagnostics
GmbH,Penzberg, Germany) or 12 h at 37 C using Mnl
(New England Biolab, Beverly, MA) restriction enzymes. Mae-
III restriction enzyme digested the PCR product of G allele
(135 bp) of -403G/A polymorphism into a visible band at
112 bp and non-visible band at 23 bp while not affecting the
mutant A allele. Mnl restriction enzyme was used for digestion
of the PCR product of C allele (173 bp) of -28C/G polymor-
phism into three fragments of 126, 27, and 20 bp for the C al-
lele and two fragments of 146 and 20 bp for the G allele. The
digestion products were analyzed on a 3.5% agarose gel
stained with ethidium bromide [19,20].
Statistics. The collected data were organized, tabulated and
statistically analyzed using SPSS software statistical computer
package version 17. The number and percent distribution of
data were calculated. Chi square was used as a test of signiﬁ-
cance and when found inappropriate Fisher exact test was
used. Odds ratio was calculated as an estimate of risk with
95% conﬁdence interval. Correlation between variables was
evaluated using Pearson’s correlation coefﬁcient. Signiﬁcance
was adopted at p< 0.05 for interpretation of results of tests
of signiﬁcance [21].
3. Results
3.1. Serum level of RANTES
Serum level of RANTES was signiﬁcantly higher in active
(23655.172 ± 2726.502) than inactive RA patients
(17616.667 ± 1961.542) and both were signiﬁcantly higher
than the controls group (12613.333 ± 1964.276) (p< 0.001)
(Table 1).
RANTES ROC curve between active and inactive RA
patients demonstrated that at serum cutoff level of >20300,
sensitivity of the test is 86.2%, speciﬁcity is 94.4% with accu-
racy of 96.9%, PPV of 96.2% and NPV of 81.0% (Fig. 1).
In active RA patients, serum RANTES level was positively
correlated with number of swollen joints, ESR, CRP, TLC and
DAS 28. But, no correlations were found with age, disease
duration, number of tender joints, and RF. On the other hand,no signiﬁcant correlations were found between serum RAN-
TES levels and any of the tested variables in inactive RA pa-
tients (Table 2).
3.2. Identiﬁcation of RANTES genotypes
As regards 403G/A, it was found that GA and AA genotypes
were more frequent among RA patients than in controls
(34.04%, 25.53% vs 13.33% respectively) while GG genotype
was signiﬁcantly less frequent among RA patients than in con-
trol group (40.43% vs 73.33% respectively p= 0.026). Conse-
quently, there was increased frequency of A carrier and A
allele in RA patients than in controls (29.79%, 42.55% vs
13.33%, 20%). Individuals with A allele were at signiﬁcant po-
sitive risk for RA but G allele were at negative risk for RA
(OR= 2.963, 95%CI = 1.108–7.923) (Table 3).
As regards disease activity, it was found that GA and AA
genotypes were more frequent among active RA patients than
in inactive group (48.27%, 27.58% vs 22.22%, 11.11% respec-
tively p= 0.739, 0.036) while GG genotype was signiﬁcantly
less frequent among active RA patients than in inactive
(24.13% vs 66.66% respectively p= 0.005). There was in-
creased frequency of A carrier and A allele in active RA pa-
tients compared to inactive patients(37.93%, 60.34% vs
16.67%,22.22%). Individuals with A allele were at signiﬁcant
positive risk for RA but G allele were at negative risk for
RA (OR= 4.565, 95%CI = 1.752–11.892) (Table 4).
Regarding promoter -28 C/G genotype polymorphism, it
was found that GG and CG genotypes were more frequent
among RA patients than in controls (8.50%, 14.90 vs 6.67%,
13.33%, respectively) while CC genotype was less frequent
among RA patients than controls (76.60% vs 80% respectively
p= 0.546). Slight increase in the G carrier and G allele fre-
quency was noticed in RA patients but the difference was
non-signiﬁcant (p= 0.461 and 0.391 respectively). Individuals
with G allele were at no relative risk for RA compared with
those of C allele (OR = 1.424, 95%CI = 0.437–4.636) (Table
5).
With respect to disease activity, it was found that CC geno-
type was more frequent among active RA patients than in
inactive ones (79.31% vs 72.31% respectively p= 0.414) while
CG and GG genotype was less frequent among RA active pa-
tients than in inactive group (13.79%,89.60% vs 16.67%,
11.11% respectively p= 0.550, 0.498). Collectively G and C
alleles’ frequency in RA patients was 13.79% and 86.21%
which was higher than its frequency in inactive patients
(19.44%, 80.56% respectively). G allele carriers were at no rel-
ative risk for RA compared with C allele carriers.
(OR = 0.663, 95%CI = 0.218–2.017) (Table 6).
Relation between serum RANTES level and -403 gene
polymorphism in active and inactive groups showed that ser-
um RANTES level was higher in AA genotype than GA geno-
type and both were higher than GG genotype and this increase
was more observed in active than inactive group (Fig. 2).
4. Discussion
Chemokines were initially thought as simple chemoattractants
but are now implicated in many areas of biomedicine. They
play a crucial role in tissue homeostasis, especially in the im-
mune system. Inappropriate activation of the chemokine net-
Table 3 Genotype, allele and allele carrier frequencies of RANTES
Patient Control
N % N %
G/G 19 40.43 11 73.33
G/A 16 34.04 2 13.33
A/A 12 25.53 2 13.33
A carrier 28 29.79 4 13.33
A allele 40 42.55 6 20.00
G allele 54 57.44 24 80.00
* Signiﬁcantly different at p < 0.05.
Table 2 Correlations of serum RANTES concentrations with clinic
Variable RANTES
Group I (active RA)
r p
Age 0.128
Duration/years 0.155
Number of swollen joints 0.982 <
Number of tender joints 0.274
ESR 0.991 <
CRP 0.796 <
RF 0.151
TLC 0.672 <
DAS 28 0.839 <
* Signiﬁcant correlation.
Table 1 Serum level of RANTES in patients of RA and control group.
RANTES ANOVA
Range Mean ± SD f p-Value
Group I (active) 19200–27700 23655.172 ± 2726.502
Group II (inactive) 13800–21200 17616.667 ± 1961.542 58.633 <0.001*
Group III (control) 10400–17300 12613.333 ± 1964.276
Tukey’s test
Groups I & II Groups I & III Groups II & III
<0.001* <0.001* 0.021*
* Signiﬁcantly different at p < 0.05.
Figure 1 ROC curve between Active and Inactive as regards
serum RANTES level.
88 H.M. Elsaadany et al.work is associated with a variety of pathological conditions,
including allergic diseases and inﬂammatory arthritis [22].
So, the present study was conducted to measure serum
RANTES concentrations, as one of the most important che-
mokines in inﬂammatory conditions, in an attempt to deter-
mine its correlation with clinical manifestations and disease
activity. The possibility that RANTES gene polymorphisms
are associated with the development and activity of RA in a
Egyptian population was investigated
This study showed that RANTES serum level was signiﬁ-
cantly higher in RA patients than in control group with more
signiﬁcant increase in active than in inactive patients.
These results came in accordance with the study of Wu et
al. [23] and Yang et al. [22] on adult RA and Yao et al. [24]
on juvenile RA who found that serum levels of RANTES in
active RA patients were signiﬁcantly higher than those of the
healthy controls. The role of chemokines in RA was explained-403G/A in patients and controls.
p-Value Odd CI 95% for odd
L U
0.026* 0.247 0.068 0.891
0.193 3.355 0.673 16.722
0.484 2.229 0.438 11.337
0.028* 3.182 1.025 9.880
0.03* 2.963 1.108 7.923
0.03* 0.338 0.126 0.903
al and laboratory variables in both RA groups.
Group II (inactive RA)
-Value r p-Value
0.507 0.378 0.122
0.423 0.273 0.272
0.001* 0.055 0.828
0.150 0.012 0.962
0.001* 0.152 0.548
0.001* 0.011 0.966
0.652 0.227 0.286
0.001* 0.121 0.348
0.001* 0.186 0.460
Table 4 Genotype, allele and allele carrier frequencies of RANTES-403G/A with respect to disease activity.
Active Inactive p-Value Odd CI 95% for odd
N % N % L U
G/G 7 24.13 12 66.66 0.005* 0.159 0.043 0.582
G/A 9 48.27 4 22.22 0.739 1.575 0.404 6.146
A/A 13 27.58 2 11.11 0.036* 6.5000 1.258 33.579
A carrier 22 37.93 6 16.67 0.023* 3.056 1.097 8.512
A allele 35 60.34 8 22.22 0.002* 4.565 1.752 11.892
G allele 23 39.66 28 77.78 0.001* 0.188 0.073 0.483
* Signiﬁcantly different at p < 0.05.
Table 5 Genotype, allele and allele carrier frequencies of RANTES-28 C/G in patients and controls.
Patient Control p-Value Odd CI 95% for odd
N % N % L U
C/C 36 76.60 12 80.00 0.546 0.818 0.195 3.433
C/G 7 14.90 2 13.33 0.625 1.138 0.210 6.174
G/G 4 8.50 1 6.67 0.651 1.302 0.134 12.641
G carrier 11 11.70 3 10.00 0.461 1.369 0.358 5.239
G allele 15 15.96 4 13.33 0.391 1.424 0.437 4.636
C allele 79 84.04 26 86.67 0.231 1.621 0.617 4.257
Table 6 Genotype, allele and allele carrier frequencies of RANTES-28 C/G with respect to disease activity.
Active Inactive p-Value Odd CI 95% for odd
N % N % L U
C/C 23 79.31 13 72.31 0.414 1.474 0.375 5.790
C/G 4 13.79 3 16.67 0.550 0.800 0.157 4.075
G/G 2 89.60 2 11.11 0.498 0.593 0.076 4.627
G carrier 6 10.34 5 13.89 0.418 0.715 0.201 2.541
G allele 8 13.79 7 19.44 0.327 0.663 0.218 2.017
C allele 50 86.21 29 80.56 0.327 1.509 0.496 4.590
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Figure 2 Relation between serum RANTES level and -403 gene
polymorphism in active and inactive groups.
RANTES as a predictor for rheumatoid arthritis susceptibility and activity in Egyptians 89by Haringman et al. [25] who reported that chemokines help
migration of mononuclear cells into synovium, leading to the
initiation and progression of the disease thus, enhancing the
inﬂammation, by recruiting, and activating leukocyte subpop-
ulations. Szekanecz et al. [26] added that chemokines intensify
inﬁltration of synovial tissue by inﬂammatory cells through the
stimulation of neovascularisation of rheumatoid synovium
which may explain the increased serum level.In this study, RANTES ROC curve between active and
inactive RA patients demonstrated that serum RANTES level
may serve as a useful marker for monitoring disease activity as
sensitivity of the test was 86.2%, speciﬁcity was 94.4% with
accuracy of 96.9% at serum cutoff level of >20300.
These results taken together with studies of Yao et al. [24]
and Yang et al. [22] who found that serum RANTES level in
RA was more strongly correlated with disease activity than
either the CRP or ESR. They also found a relationship
between serum RANTES level and the duration of clinical
remission, with low level of RANTES being associated with
prolonged clinical remission and high level with shortened clin-
ical remission, indicating that serum RANTES can be used as
predictor for RA activity.
The correlation of RANTES in RA with parameters of dis-
ease activity number of swollen joints, CRP, ESR and DAS28
which were found in this work is largely conﬁrmed by the pre-
vious works of Klimiuk et al. [27] Klimiuk et al. [1] and Yang
et al. [22].
Genetic studies on the RANTES gene have identiﬁed two
point polymorphisms or single nucleotide polymorphisms in
the promoter region, G-to-A substitution at position 403 and
C-to-G substitution at position 28 in autoimmune and inﬂam-
matory diseases [28].
90 H.M. Elsaadany et al.In the present study, -403 gene polymorphism revealed that
GA and AA genotypes were signiﬁcantly higher among RA
patients than in controls. On the contrary, GG genotype was
signiﬁcantly less frequent. So, there was increased frequency
of A carrier and A allele in RA patients than in control which
means that individuals with A allele were at signiﬁcant positive
risk for RA compared with G allele.
The increased frequency of AA genotype and A allele in
RA patients came in agreement with the results of Wang et
al. [29] on Chinese RA patients, however, in their study the
GA genotype and carrier rate of A allele were nearly similar
between patients and controls. Moreover, Pulsatelli et al. [30]
and Makki et al. [11] had reported clinical associations of
RANTES A-403 with inﬂammatory diseases such as polymyal-
gia rheumatica, and rheumatoid arthritis.
As regards promoter -28 C/G genotype polymorphism, it
was found that GG and CG genotypes were more frequent
among RA patients than in controls while CC genotype was
less frequent. Slight increase in frequency of G allele was no-
ticed in RA patients but the difference was non-signiﬁcant.
So, G carriers were at no relative risk for RA compared with
those of C allele carriers. Similarly, Wang et al. [29]found
slight increase in the frequency of G allele and G carriers of
the promotor -28 in RA patients but the difference was not sta-
tistically signiﬁcant. This may be explained by the suggestion
that RANTES transcription has been shown to up regulate
by SNPs in the RANTES regulatory regions -28G and -
403A, however, -28G has a weaker up-regulating effect [8].
Another possible explanation is that of Yao et al. [31] who re-
ported that, an observed effect for a polymorphism might
actually be attributable to a nearby gene variant considering
that the effect of the RANTES-403A allele might be a reﬂec-
tion of linkage disequilibrium with the nearby RANTES-
28G allele.
As an initial step to link RANTES (-403 G/A) polymor-
phism and its serum levels, the current study, showed that ser-
um RANTES level was higher in AA genotype than GA
genotype and both were higher than GG genotype and this in-
crease was more observed in active than inactive group. This
relation previously studied by Tian et al. [32] during the acute
phase of RSV bronchiolitis who reported that the serum RAN-
TES levels were up-regulated in individuals who carried the -
403 A allele so, they believed that RANTES has a regulatory
role in the inﬂammatory process. Also, the A-403 variant has
been associated with functional and biological effects in the
promoter region of the RANTES gene resulted in up to 8-fold
increased constitutive transcriptional activity [9]. These results
indicate that RANTES-403 A may be responsible for elevated
transcriptional activity, resulting in high serum RANTES lev-
els in A-allele individuals.
In conclusion, serum RANTES level is signiﬁcantly ele-
vated in RA patients than controls. Moreover, it can be used
as a useful marker of the disease activity as it correlated sig-
niﬁcantly with the other parameters of activity. The polymor-
phisms within the RANTES promoter at position -403 G/A
showed that AA genotype and A allele frequencies were sig-
niﬁcantly higher in RA patients which was more obvious in
active group. On the other hand, polymorphism at posi-
tion-28 C/G had a non-signiﬁcant increased frequency of
GG genotype and G allele among RA patients than in
controls. These results may suggest that RANTES-403G/Apolymorphism may contribute to the susceptibility and activ-
ity of Egyptian RA.
Based on the experimental study of Shahrara et al. [33] that
treatment of adjuvant induced arthritis, by the inhibition of
RANTES with methionylated RANTES (Met-RANTES),
resulted in decrease joint inﬂammation, proinﬂammatory cyto-
kines, bone destruction, and cell recruitment into the ankles.
Therapeutic modulation of high RANTES level may lead to
the development of effective alternative treatment for RA.The
association of A allele at position 403 of RANTES gene with
susceptibility and activity of RA may enable rheumatologists
to deﬁne RA patients who are at risk of activity. Patients with
A allele risk categories could be monitored more closely, by
determining serum RANTES levels, or they may be targeted
for more aggressive therapies.References
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